Dr. Timothy Eric Bael, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 201 Harris B Dates Dr, Suite 102, Ithaca, NY 14850 Phone: 607-272-5414 Fax: 607-272-6121 |
Dr. Charles L Garbo, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 201 Harris B Dates Dr, Suite 102, Ithaca, NY 14850 Phone: 607-272-5414 Fax: 607-272-6121 |
Nisha Elizabeth Ajit, MBBS Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 201 Harris B Dates Dr Ste 102, Ithaca, NY 14850 Phone: 607-272-5414 |
News Archive
Regis Technologies, Inc., a leading provider of cGMP and non-GMP synthesis and separations services for active pharmaceutical ingredients (APIs) and intermediates, announced it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) stating that Regis passed the FDA's pre-approval inspection (PAI) for its manufacture of 4-Aminopyridine the active ingredient in Ampyraâ„¢.
Children who spend time in a neonatal intensive care unit at birth have a higher risk of mental health issues later, regardless of their birth weight, say McMaster University researchers.
With the U.N. Human Rights Council's June session coming up, governments have a "chance to prove that they value women's lives by taking concrete action" to recognize "preventable maternal death as a violation of women's rights," Mary Robinson and Alicia Yamin, advisory council members of the International Initiative on Maternal Mortality and Human Rights, write in a Boston Globe opinion piece.
Researchers from Plymouth University Peninsula Schools of Medicine and Dentistry have received one of the prestigious 2014 Oral and Dental Research Trust-GSK Research Awards from the British Society of Oral and Dental Research, for a research project which seeks to re-programme the immune system to stop bone destruction and tooth loss in severe gum disease.
Proliferative diabetic retinopathy is a major sight-threatening diabetic complication. Nearly all patients with type I diabetes and over 60% of patients with type II diabetes develop retinopathy after 20 years of diabetes, despite metabolic control.
› Verified 7 days ago